Frank Gray

GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species

A. Richard Rutter, Alessandro Poffe, Palmina Cavallini et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 49 citations

Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study

Joanne Ellis, André van Maurik, Léa Fortunato et al. · British Journal of Clinical Pharmacology · 2018 · 42 citations · Full text

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients

Laurence Moss, Marijke Hyke Algera, Robert L. Dobbins et al. · PLoS ONE · 2022 · 38 citations · Full text

Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine‐1‐phosphate receptor modulator, in healthy volunteers

Jianfeng Xu, Frank Gray, Alex Henderson et al. · Clinical Pharmacology in Drug Development · 2013 · 34 citations

Molecular Pharmacology, Hypertension, Heart Rate +14

Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET

Khanum Ridler, Roger N. Gunn, Graham E. Searle et al. · Journal of Psychopharmacology · 2014 · 24 citations